Injective (INJ) is currently priced at $3.36, reflecting an 8.09% increase over the past 24 hours. The price has fluctuated between a low of $2.96 and a high of $3.60 during this period, indicating strong intraday volatility.

Trading volume stands at approximately 112.99 million, representing 33.59% of the market cap, suggesting healthy liquidity and active trading interest. The daily price range of 0.64% highlights a relatively stable market, though the upward price movement indicates bullish sentiment among traders.

Analyzing moving averages reveals an upward trend, with the 8 SMA at $3.00 (+11.83%) and the 13 SMA at $3.04 (+10.57%). Longer-term averages, such as the 144 SMA at $3.13 (+7.32%), also show positive momentum, reinforcing the bullish outlook.

The one-hour Relative Strength Index (RSI) is at 72, indicating that INJ may be overbought in the short term. Conversely, the 7-day RSI at 56 suggests that the asset is approaching neutral territory, allowing for potential continued upward movement.

Over the past week, INJ has appreciated by 10.40%, while the 14-day and 30-day price changes are -4.09% and -30.28%, respectively, indicating short-term recovery after a more extended downtrend. This price action, coupled with a significant distance from its all-time high of $52.62, suggests that there may be substantial room for growth.

In summary, the current bullish momentum, solid trading volume, and positive moving averages indicate a favorable environment for INJ. Given the short-term overbought conditions balanced by medium-term recovery potential, I recommend a **Hold** rating for Injective at this time, with an eye on market conditions for possible re-entry or profit-taking strategies.